Back to Journals » Neuropsychiatric Disease and Treatment » Volume 14

Alzheimer's disease and blood-based biomarkers – potential contexts of use

Authors Zvěřová M

Received 25 April 2018

Accepted for publication 22 May 2018

Published 20 July 2018 Volume 2018:14 Pages 1877—1882

DOI https://doi.org/10.2147/NDT.S172285

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Roger Pinder


Martina Zvěřová1,2

1Department of Psychiatry, General University Hospital in Prague, Prague, Czech Republic; 2First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

Abstract: Alzheimer’s disease (AD) is an irreversible, incurable, progressive neurodegenerative illness, where dementia symptoms gradually worsen over a number of years. The research of validated biomarkers for AD is essential to improve diagnosis and accelerate the development of new therapies. Biochemical markers including neuroimaging could facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment, and be used to detect the efficacies of disease-modifying therapies. Established biomarkers of AD from cerebrospinal fluid and neuroimaging are highly accurate, but barriers to clinical implementation exist. The focus on blood-based AD biomarkers has grown exponentially during the past few decades. An ideal diagnostic test for AD should be noninvasive and easily applicable. Clinical cost-effectiveness also needs to be established.

Keywords: biomarker, Alzheimer’s disease, neurodegeneration, cerebrospinal fluid, beta amyloid, tau protein

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]